Q1 2026 · 13F-HR
BAKER BROS. ADVISORS LPholdings as filed
Filed 2026-05-15 · accession 0001104659-26-062547
$17.42B
Reported value
84
Positions
2026-03-31
Period end
The Brief · BAKER BROS. ADVISORS LP · Q1 2026
AI · grounded in 13F
BAKER BROS. ADVISORS LP exited its position in Ultragenyx Pharmaceutical Inc. RARE, reducing its exposure by $63.8M. The fund also closed positions in Terns Pharmaceuticals, Inc. 430 and BioCryst Pharmaceuticals, Inc. BCRX, while initiating a new position in Mirum Pharmaceuticals, Inc. MIRM worth $41.2M. Additionally, the fund increased its holdings in Enliven Therapeutics, Inc. ELVN by 233.5% and Praxis Precision Medicines, Inc. PRAX by 55.6%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 45337C102 | INCY | Incyte Corporation | $2.89B | 16.6% | 30,744,412 | Common | SOLE |
| 07725L102 | ONC | BeOne Medicines Ltd. | $2.61B | 15.0% | 8,799,053 | Common | SOLE |
| 457669307 | INSM | Insmed Incorporated | $1.21B | 6.97% | 7,421,111 | Common | SOLE |
| 558868105 | MDGL | Madrigal Pharmaceuticals, Inc. | $1.12B | 6.44% | 2,141,701 | Common | SOLE |
| 004225108 | ACAD | ACADIA Pharmaceuticals Inc. | $954.9M | 5.48% | 42,896,690 | Common | SOLE |
| 76155X100 | RVMD | Revolution Medicines, Inc. | $929.3M | 5.34% | 9,555,357 | Common | SOLE |
| 15102K100 | CELC | Celcuity Inc. | $903.5M | 5.19% | 7,915,792 | Common | SOLE |
| 50015M109 | KOD | Kodiak Sciences Inc. | $759.3M | 4.36% | 19,919,186 | Common | SOLE |
| 501575104 | KYMR | Kymera Therapeutics, Inc. | $721.1M | 4.14% | 8,657,242 | Common | SOLE |
| 86627T108 | SMMT | Summit Therapeutics Inc. | $690.0M | 3.96% | 36,391,063 | Common | SOLE |
| 74006W207 | PRAX | Praxis Precision Medicines, Inc. | $564.9M | 3.24% | 1,753,198 | Common | SOLE |
| 76243J105 | RYTM | Rhythm Pharmaceuticals, Inc. | $487.4M | 2.80% | 5,604,483 | Common | SOLE |
| G01767105 | ALKS | Alkermes plc | $354.0M | 2.03% | 10,012,267 | Common | SOLE |
| 384747101 | GRAL | GRAIL, Inc. | $208.2M | 1.20% | 4,028,614 | Common | SOLE |
| 28036F105 | EWTX | Edgewise Therapeutics, Inc. | $207.1M | 1.19% | 6,575,940 | Common | SOLE |
| 462222100 | IONS | Ionis Pharmaceuticals, Inc. | $153.8M | 0.88% | 2,047,727 | Common | SOLE |
| G52694109 | KNSA | Kiniksa Pharmaceuticals International, plc | $136.1M | 0.78% | 2,826,246 | Common | SOLE |
| 45258J102 | IMVT | Immunovant, Inc. | $135.6M | 0.78% | 5,457,881 | Common | SOLE |
| G76279101 | ROIV | Roivant Sciences Ltd. | $134.8M | 0.77% | 4,867,723 | Common | SOLE |
| 45166A102 | IDYA | IDEAYA Biosciences, Inc. | $131.5M | 0.76% | 3,946,515 | Common | SOLE |
| 04280A100 | ARWR | Arrowhead Pharmaceuticals, Inc. | $124.9M | 0.72% | 1,992,783 | Common | SOLE |
| 86150R107 | STOK | Stoke Therapeutics, Inc. | $108.6M | 0.62% | 3,336,697 | Common | SOLE |
| N44445109 | IMTX | Immatics N.V. | $107.4M | 0.62% | 10,916,693 | Common | SOLE |
| 00288U106 | ABCL | AbCellera Biologics Inc. | $105.7M | 0.61% | 30,275,938 | Common | SOLE |
| 00370M103 | ABVX | Abivax S.A. | $97.5M | 0.56% | 875,796 | Common | SOLE |
| 22663K107 | CRNX | Crinetics Pharmaceuticals, Inc. | $85.4M | 0.49% | 2,351,465 | Common | SOLE |
| 76029N106 | REPL | Replimune Group, Inc. | $84.5M | 0.49% | 11,045,336 | Common | SOLE |
| 15102KAA8 | CELC 2.75 08/01/31 | Celcuity Inc. | $74.9M | 0.43% | 30,750,000 | Common | SOLE |
| 67080M103 | NRIX | Nurix Therapeutics, Inc. | $72.2M | 0.41% | 4,658,556 | Common | SOLE |
| 24823R105 | DNLI | Denali Therapeutics Inc. | $71.6M | 0.41% | 3,731,695 | Common | SOLE |
| 252828108 | DNTH | Dianthus Therapeutics, Inc. | $71.5M | 0.41% | 852,164 | Common | SOLE |
| 61225M102 | GLUE | Monte Rosa Therapeutics, Inc. | $71.5M | 0.41% | 4,345,736 | Common | SOLE |
| 86366E106 | GPCR | Structure Therapeutics Inc. | $69.0M | 0.40% | 1,432,529 | Common | SOLE |
| 29384C108 | TRDA | Entrada Therapeutics, Inc. | $64.0M | 0.37% | 5,072,730 | Common | SOLE |
| 088786108 | BCYC | Bicycle Therapeutics plc | $50.5M | 0.29% | 10,885,357 | Common | SOLE |
| 00773J202 | SYRE | Spyre Therapeutics, Inc. | $50.4M | 0.29% | 1,000,000 | Common | SOLE |
| 75383L102 | RAPP | Rapport Therapeutics, Inc. | $48.4M | 0.28% | 1,547,090 | Common | SOLE |
| 022307102 | ALMS | Alumis Inc. | $44.3M | 0.25% | 2,012,500 | Common | SOLE |
| 604749101 | MIRM | Mirum Pharmaceuticals, Inc. | $41.2M | 0.24% | 445,975 | Common | SOLE |
| 92790C104 | VRDN | Viridian Therapeutics, Inc. | $38.6M | 0.22% | 1,971,678 | Common | SOLE |
| 29337E102 | ELVN | Enliven Therapeutics, Inc. | $35.5M | 0.20% | 905,191 | Common | SOLE |
| 74065P101 | PRLD | Prelude Therapeutics Inc. | $34.6M | 0.20% | 10,123,824 | Common | SOLE |
| 23306J309 | DBVT | DBV Technologies S.A. | $30.5M | 0.18% | 1,461,425 | Common | SOLE |
| 25056L103 | DSGN | Design Therapeutics, Inc. | $27.5M | 0.16% | 2,585,978 | Common | SOLE |
| 152309100 | CNTA | Centessa Pharmaceuticals plc | $26.6M | 0.15% | 670,751 | Common | SOLE |
| 23284F105 | CTMX | CytomX Therapeutics, Inc. | $23.4M | 0.13% | 4,975,826 | Common | SOLE |
| 008064206 | JBIO | Jade Biosciences, Inc. | $23.1M | 0.13% | 1,641,137 | Common | SOLE |
| 254604101 | IRON | Disc Medicine, Inc. | $22.4M | 0.13% | 349,657 | Common | SOLE |
| 45258D105 | IMCR | Immunocore Holdings plc | $22.1M | 0.13% | 734,397 | Common | SOLE |
| 98420N105 | XENE | Xenon Pharmaceuticals Inc. | $21.5M | 0.12% | 370,208 | Common | SOLE |
| 15117B202 | CLDX | Celldex Therapeutics, Inc. | $21.1M | 0.12% | 665,370 | Common | SOLE |
| 64135M105 | NGNE | Neurogene Inc. | $20.0M | 0.11% | 991,691 | Common | SOLE |
| 30054Y107 | EVMN | Evommune, Inc. | $19.5M | 0.11% | 847,390 | Common | SOLE |
| 878972108 | TECX | Tectonic Therapeutic, Inc. | $18.8M | 0.11% | 607,788 | Common | SOLE |
| 21217B100 | CTNM | Contineum Therapeutics, Inc. | $18.6M | 0.11% | 1,420,838 | Common | SOLE |
| 04016X101 | ARGX | argenx SE | $18.4M | 0.11% | 25,174 | Common | SOLE |
| 157085101 | CERS | Cerus Corporation | $18.2M | 0.10% | 10,008,345 | Common | SOLE |
| 877619106 | TSHA | Taysha Gene Therapies, Inc. | $17.9M | 0.10% | 4,004,756 | Common | SOLE |
| 01021M104 | AKTS | Aktis Oncology, Inc. | $17.8M | 0.10% | 996,351 | Common | SOLE |
| 370920100 | GENB | Generate Biomedicines, Inc. | $17.8M | 0.10% | 1,423,602 | Common | SOLE |
| 829401108 | SION | Sionna Therapeutics, Inc. | $16.0M | 0.09% | 400,000 | Common | SOLE |
| 26818M108 | DYN | Dyne Therapeutics, Inc. | $14.7M | 0.08% | 813,449 | Common | SOLE |
| 98401F105 | XNCR | Xencor, Inc. | $13.3M | 0.08% | 1,102,106 | Common | SOLE |
| 20451W101 | CMPS | COMPASS Pathways plc | $13.0M | 0.07% | 2,344,720 | Common | SOLE |
| 75943R102 | RLAY | Relay Therapeutics, Inc. | $11.5M | 0.07% | 1,160,117 | Common | SOLE |
| 81749D107 | SERA | Sera Prognostics, Inc. | $11.2M | 0.06% | 5,498,170 | Common | SOLE |
| 09075V102 | BNTX | BioNTech SE | $10.6M | 0.06% | 119,743 | Common | SOLE |
| N69605108 | PHVS | Pharvaris N.V. | $10.6M | 0.06% | 375,000 | Common | SOLE |
| 03969F109 | RCUS | Arcus Biosciences, Inc. | $9.0M | 0.05% | 415,621 | Common | SOLE |
| 56565P103 | MPLT | MapLight Therapeutics, Inc. | $7.4M | 0.04% | 364,705 | Common | SOLE |
| 00091E109 | ABSI | Absci Corporation | $6.4M | 0.04% | 2,134,803 | Common | SOLE |
| Y95308105 | WVE | Wave Life Sciences Ltd. | $6.0M | 0.03% | 822,638 | Common | SOLE |
| 918385204 | VTVT | vTv Therapeutics, Inc. | $5.9M | 0.03% | 148,314 | Common | SOLE |
| 282564103 | EIKN | Eikon Therapeutics, Inc. | $5.9M | 0.03% | 555,555 | Common | SOLE |
| 74365U107 | TARA | Protara Therapeutics, Inc. | $5.1M | 0.03% | 971,614 | Common | SOLE |
| 786700104 | SGMT | Sagimet Biosciences Inc. | $5.0M | 0.03% | 952,996 | Common | SOLE |
| 50180M108 | LBRX | LB Pharmaceuticals Inc. | $4.9M | 0.03% | 200,000 | Common | SOLE |
| 92337C203 | VSTM | Verastem, Inc. | $3.1M | 0.02% | 584,757 | Common | SOLE |
| 89854M101 | TCRX | TScan Therapeutics, Inc. | $2.8M | 0.02% | 2,784,792 | Common | SOLE |
| 83086J200 | SKYE | Skye Bioscience, Inc. | $968,144 | 0.01% | 1,575,243 | Common | SOLE |
| 799566104 | SANA | Sana Biotechnology, Inc. | $894,191 | 0.01% | 310,483 | Common | SOLE |
| 01626L204 | ALGS | Aligos Therapeutics, Inc. | $617,099 | 0.00% | 83,055 | Common | SOLE |
| 90240B106 | TYRA | Tyra Biosciences, Inc. | $406,248 | 0.00% | 10,607 | Common | SOLE |
| 86889P117 | SRZNW | Surrozen, Inc. | $13,333 | 0.00% | 833,333 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.